Protara Therapeutics, Inc. (TARA)

Market Cap	36.06M
Revenue (ttm)	n/a
Net Income (ttm)	-40.30M
Shares Out	11.27M
EPS (ttm)	-3.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,496
Open	2.99
Previous Close	2.96
Day's Range	2.93 - 3.27
52-Week Range	2.72 - 7.97
Beta	1.50
Analysts	Buy
Price Target	34.43 (+975.9%)
Earnings Date	Nov 2, 2022

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed ...

• Industry: Biotechnology
• CEO: Jesse Shefferman
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TARA stock is "Buy." The 12-month stock price forecast is 34.43, which is an increase of 975.94% from the latest price.

Price Target

$34.43

(975.94% upside)

Analyst Consensus: Buy

Stock Forecasts